Get the app
public
ios_share
OncoPharm
chevron_right
Pralsetinib
Sep 11, 2020
11:47
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
